Invitrogen™ Alirocumab Recombinant Human Monoclonal Antibody

Catalog No.	Quantity
PIMA541963	100 μg

Catalog No. PIMA541963 Supplier Invitrogen™ Supplier No. MA541963

Description

Human Recombinant Monoclonal Antibody

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.

Specifications

• Antigen: Alirocumab
• Applications: ELISA, Flow Cytometry
• Classification: Recombinant Monoclonal
• Concentration: 2.18 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with no preservative; pH 7.4
• Gene Alias: REGN727; SAR-236553
• Host Species: Human
• Immunogen: Human PCSK9.
• Purification Method: Protein A/G
• Quantity: 100 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Target Species: Human
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG1 κ
• Target Molecule: Chemical